ACON🟢-Aclarion.Inc -$ 25

Why investors can be confident: ✅ Even if the share price on the market is slightly below the offering price, the total amount of capital raised is still $10.36 million, significantly strengthening the company's balance sheet. ✅ Cash after the deal = $22-23 million → increases the runway and reduces the immediate need for new offerings until 2027. ✅ Pricing the offering close to the market ⚠️minimizes the risk of significant⚠️ price pressure after the RDO closes. 🟢The RDO at $5.18 is above the market price of $4.80, but not critically so. ✅ Share dilution compared to the previous offering is minimal, as the price is already close to the market. ✅ This confirms the company's financial stability for the next 1.5-2 years. 🎙️Brent Ness, CEO of Aclarion: "We are pleased with the company's progress in strengthening our financial position, expanding our clinical presence, and advancing Nociscan's adoption." It was also noted that the company's cash position and lack of debt provide confidence in funding operations through 2027. That is, these are practical statements that in the next 24 months there will be no more additional issues, since they have enough money, and this statement is supported by the forecast for shares to reach $25 in the near future.🚀🚀🚀